Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in Cyclo Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CYTH is no longer listed, and 13F filings after Q4 2024 list far fewer holders. See Q4 2024
- Institutional holders
- 0
- −21 vs. Q4 2024
- Shares held
- 0
- −1.57M (−100.0%) vs. Q4 2024
- Total value
- $0
- −$927.7K (−100.0%) vs. Q4 2024
- New holders
- 0
- 0 more added
- Sold out
- 21
- 0 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 0 | $0 | 0.00% | −598,694−100.0% | Sold out |
| Founders Fund V Management, LLC | 0 | $0 | 0.00% | −480,708−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −152,332−100.0% | Sold out |
| Founders Fund VI Management, LLC | 0 | $0 | 0.00% | −110,023−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −83,822−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −42,541−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −39,530−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −21,736−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −18,285−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −11,987−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −6,684−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −4,391−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1,031−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −193−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −170−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −90−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −67−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −746−100.0% | Sold out |
| EPIQ Capital Group, LLC | – | – | – | – | Not filed |